{"entity":{"id":"nct06084884","kind":"trial","name":"A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma","aka":[],"tldr":"A phase 1/2 trial of AZD5851 in hepatocellular carcinoma, run by AstraZeneca, active and no longer recruiting.","summary":"A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma is a phase 1/2 interventional study registered as NCT06084884 by AstraZeneca, with 94 participants enrolled, started 2023-12-14 and due to reach its primary completion in 2027-12-13. Interventions recorded: AZD5851.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06084884","url":"https://clinicaltrials.gov/study/NCT06084884"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06084884","phase":"1/2","setting":"A Phase I/II Open-Label Study to Evaluate the Safety, Cellular Kinetics and Efficacy of AZD5851, a Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Directed Against GPC3 in Adult Participants With Advanced/Recurrent Hepatocellular Carcinoma: ATHENA","sponsor":"AstraZeneca","enrolled":94,"outcomes":[]},"route":"/trials/nct06084884/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}